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Abstract
The adenocarcinoma of the colon and rectum (CRC) affects more than 1.3 
million patients each year, being the third most common malignancy in the 
world. Approximately, 30–50% of these patients will present with liver metas-
tasis at the time of diagnosis or will develop metastasis later. The incidence of 
metastatic CRC (mCRC) is approximately 4.3% at 1 year, 8.7% at 2 years, 12% 
at 3 years, and 16.5% at 5 years after resection. Recently, the clinical outcome 
for patients with mCRC has improved, with a median overall survival (OS) 
for patients with mCRC is approximately 30 months, more than twice of that 
observed 20 years ago. The treatment approach for patients with colorectal liver 
metastases should be focused toward complete resection whenever possible, 
with both oncological and technical criteria being considered. Considering the 
fact that nearly 80% of patients with mCRC are not candidates for resection 
at diagnosis, initial treatment options include chemotherapy and locoregional 
therapies. Associating liver partition and portal vein ligation for staged hepatec-
tomy (ALPPS) has emerged as modification on classic two-staged hepatectomy 
(TSH) with portal vein embolization. In experienced hepatobiliary centers and 
in well-selected patients, ALPPS can be performed with low morbidity and 
minimal mortality, resulting in good intermediate-term survival and excellent 
quality of life. Multidisciplinary tumor boards should critically scrutinize the 
best treatment options.
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1. Introduction
The adenocarcinoma of the colon and rectum (CRC) affect more than 1.3 mil-
lion patients each year, being the third most common malignancy in the world [1]. 
Approximately, 30–50% of these patients will present with liver metastasis at the 
time of diagnosis or will develop metastasis later [2, 3].
Due to the fact that venous drainage of the intestinal tract is via the portal sys-
tem, the first site of hematogenous spreading is usually the liver. The most common 
site of metastatic CRC is the liver, occurring in 80% of cases, representing nearly 
half of all patients with CRC. It is also the single site of metastasis in 20–50% of the 
cases [2]. The majority of metastatic CRC liver disease will be potentially resectable 
at the time of diagnosis, approximately 75–80% of cases [3]. Recurrence after resec-
tion of the primary lesion depends on the stage. The overall recurrence rate ranges 
from 9% in stage 1–56% in stage 3 CRC tumors [3].
A majority of CRC metastases (mCRC) occurs within the first 3 years. The 
incidence of mCRC is approximately 4.3% at 1 year, 8.7% at 2 years, 12% at 
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3 years, and 16.5% at 5 years after resection [2]. The frequency of metachronous 
CRC metastases is highly variable in the literature, arising from database differ-
ences and diversity of definitions. Metachronous CRC metastases are restricted 
to the liver in 44% of patients with distant recurrence following potentially 
curative resection of the primary lesion. In prospective and retrospective studies 
of referral centers, this rate reaches 35% [4]. In prospective observational studies 
and population studies, this frequency is lower, ranging from 5.7 to 16.3% [5]. 
In population studies, the frequency of synchronous liver metastases from CRC 
varies from 14.5 to 24% [2]. Patients presenting with stage 4 disease at the time 
of the diagnosis will have liver-confined metastases (synchronous metastases) in 
77% of the cases [6].
Recently, the clinical outcome for patients with mCRC has improved. Nowadays, 
the median overall survival (OS) for patients with mCRC is approximately 
30 months, more than twice of that observed 20 years ago [7]. It is not clear which 
improvements and/or strategic changes in the treatment and management of 
patients with mCRC in recent years have been responsible for the improved treat-
ment outcomes for these patients. Some changes that might have contributed for 
this gain in OS are (i) changes in the clinical presentation of patients, before the 
commencement of treatment, due to closer follow-up after resection of the primary 
tumor and earlier detection of metastatic disease; (ii) improvements in the effi-
cacy of systemic therapies in terms of regimens used, sequence of administration, 
number of lines of therapy administered, and biomarker-based patient selection; 
(iii) an increase in the number of patients being treated with a view to facilitating 
resection of their metastases, offering an increased number of patients the chance 
of cure and/or durable relapse-free survival and, more recently, the utilization of 
other ablative therapy techniques with the aim of achieving the same outcome; and 
(iv) implementation of “continuum of care” treatment strategies coupled with the 
early integration of optimal supportive care measures [7].
The best treatment strategies for patients with mCRC are evolving rapidly. 
Superior clinical outcomes are reached when the treatment approaches for individ-
ual patients are discussed within a multidisciplinary team (MDT) of experts, meet-
ing regularly as a tumor board to review mCRC cases [8]. The responsibility of the 
MDT is to define the initial diagnostic workup and then the treatment focus, based 
on the best diagnostic and therapeutic decision-making available. Initially, the MDT 
member should critically define whether or not a patient has clearly resectable or 
initially unresectable metastatic disease. Contrariwise, for patients whose disease is 
believed “never to be resectable,” the discussion may be left to the treating medical 
oncologist (after discussion with the MDT) and patient as to the pros and cons of 
various approaches and sequences based on the perceived aims (e.g., duration of 
disease control versus quality of life and toxicity profiles, etc.) [7].
2. Imaging
The preferred method for the diagnosis of extrahepatic disease is computed 
tomography (CT) [9–11]. It is the method of choice for staging and follow-up of 
patients with colorectal cancer, as imaging methods are widespread in our environ-
ment, familiar to oncologists, radiologists, and surgeons, with good cost/benefit. 
Therefore, the use of CT is recommended as the initial method in the diagnosis of 
extrahepatic metastases.
Magnetic resonance imaging (MRI) is the most accurate imaging technique 
for the detection and characterization of focal liver lesions. However, costs are 
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higher and it has restricted availability. Other limitations include magnetic field 
exposure and gadolinium use restrictions in patients with renal insufficiency. 
Retrospective and meta-analyses have shown that MRI has a superior sensitivity 
to TC both in analysis per patient (81.1–88.2% vs. 74.8–83.6%) and in analysis per 
lesion (80.3–86.3% vs. 74.4–82.6%); such superiority is related to higher detection 
of lesions smaller than 1 cm [12, 13]. MRI with hepatobiliary contrast has dem-
onstrated to have greater accuracy than FDG-PET/CT in detection of small liver 
metastases (92 vs. 60%) [14]. In a multicenter randomized prospective study, the 
performance of MRI with hepatobiliary contrast was superior to CT with iodin-
ated contrast and MRI with extracellular gadolinium as first-line method in the 
initial evaluation of liver mCRC [14].
PET/CT have shown to be of great value in the evaluation of extrahepatic sites of 
metastases undetected by other methods in patients eligible for surgical resection of 
liver mCRC, altering the therapeutic plan [15, 16].
Since cross-sectional imaging modalities have improved sensitivity of the diag-
nosis of mCRC, diagnostic laparoscopy is no longer standard for evaluating patients 
with mCRC. Instead, it is only used in patients with a suspicion of small-volume 
carcinomatosis on radiographic imaging studies or who are at particularly high risk 
for harboring unresectable diseases [17].
3. Prognostic determinants
The pathologic stage at presentation is the most important indicator of outcome 
after treatment in general, followed by the presence of extramural tumor depos-
its, lymphovascular and perineural invasion, histologic grade of differentiation, 
the preoperative level of serum carcinoembryonic antigen (CEA), microsatellite 
instability (MSI), and RAS and BRAF mutations [18, 19].
Microsatellite instability (MSI) status or mismatch repair deficiency (MMR-D) 
has been the biomarker for adjuvant 5-FU monotherapy and immune checkpoint 
inhibitor. Hematogenous and lymphogenous metastasis-dominant CRC with high-
frequency MSI (MSI-H) are reported to have poor prognosis. However, the validity 
as the prognostic factor of MMR is still to be confirmed, and it should thus be used 
cautiously [20, 21].
On the other hand, it is also known that RAS and BRAF mutations are of prog-
nostic and predictive value in mCRC [21]. The pathogenesis of CRC involves the 
accumulation of genetic and epigenetic modifications within pathways that regulate 
proliferation, apoptosis, and angiogenesis.
KRAS mutations involving either codon 12 or 13 can be identified in 12–75% of 
tumors, and they have been individually correlated with a worse prognosis in most 
studies [22]. BRAF V600E mutations are present in 8–10% of patients, are consis-
tently associated with poor prognosis, and result in possible patient ineligibility for 
resection of mCRC [23]. Recently, a small single-center cohort study showed that 
21 of 52 patients with BRAF V600E mutant who underwent metastasectomy had 
longer OS (29.1 vs. 22.7 months) and progression-free survival (13.6 vs. 6.2 months) 
than the non-metastasectomy cohort. The authors concluded that multimodality 
therapy incorporating metastasectomy for BRAF V600E metastatic CRC should 
be considered and might be associated with improved OS in selected patients [24]. 
Meanwhile, BRAF V600E can be a biomarker for selecting the appropriate chemo-
therapy regimen [21].
Another feature that also appears to affect the prognosis of patients who develop 
liver metastases is the embryonic origin of the primary colon cancer. In an analysis 
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of 727 patients who were submitted to chemotherapy followed by resection, mCRC 
from midgut origin (right colon tumors) was associated with worse pathologic 
response to chemotherapy and worse survival after resection than mCRC from 
hindgut origin (left/sigmoid colon tumors) [25]. This effect was independent of the 
RAS mutation status. Primary tumor from right-sided colon might be more prone to 
recur. Therefore, palliative resection might not be done since these patients showed 
no benefit from resection [26].
4. Patient selection
The treatment approach for patients with colorectal liver metastases should be 
focused toward complete resection whenever possible, with both “oncological” 
(prognostic) and “technical” (surgical) criteria being considered when evaluating 
patients for surgery [27, 28].
The “technical” definitions of resectable mCRC have evolved over time, with the 
current consensus proposing that disease should be considered technically resect-
able as long as complete macroscopic resection is feasible while maintaining at least 
a 30% future liver remnant (FLR) or a remnant liver to body weight ratio >0.5 (e.g., 
>350 g of the liver per 70 kg patient) [29]. Nevertheless, not all patients with tech-
nically resectable liver-limited metastases benefit from surgery; approximately half 
of the patients submitted to resection of mCRC will present widespread systemic 
disease within 3 years of the resection [30].
Prognostic information that predicts a longer disease-free survival (DFS) or a 
higher probability of cure is provided by the “oncological” criteria. Strong param-
eters for the oncological criteria are the number of lesions; the presence, or sus-
picion, of extrahepatic disease; and numerous other criteria used in retrospective 
studies. Fong et al. proposed a score based on the following parameters: nodal status 
of primary tumor, disease-free interval from the primary to discovery of the liver  
metastases of <12 months, number of tumors >1, preoperative CEA level >200 ng/ml,  
and size of the largest tumor >5 cm (Table 1) [31]. Thus, for some patients, neoad-
juvant chemotherapy may be a better option than upfront surgery.
In practice, the patients can be categorized, based upon the criteria above, 
whether or not they are eligible for resection, as proposed by Adam et al. (Table 2)  
[28]. The disease can be categorized as resectable, not optimally resectable, or 
unresectable. The not optimally resectable disease is defined as difficult to resect for 
technical reasons (proximity to hepatic vein and portal vein branches) or technically 
Survival (%)
Score 1 year 2 year 3 year 4 year 5 year Median (mo)
0 93 79 72 60 60 74
1 91 76 66 54 44 51
2 89 73 60 51 40 47
3 86 67 42 25 20 33
4 70 45 38 29 25 20
5 71 45 27 14 14 22
Each risk factor is one point: node-positive primary, disease-free interval <12 months, >1 tumor, size >5 cm, CEA 
>200 ng/ml.
Table 1. 
Clinical risk score for tumor recurrence proposed by Fong et al. [31].
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possible to resect, but oncologically problematic (number of liver metastases greater 
than 4, maximum diameter 5 cm or more, synchronous liver metastases, primary 
lymph node metastasis positive, and high levels of tumor markers) [32].
5. Treatment options
Considering the fact that nearly 80% of patients with mCRC are not candidates 
for resection at diagnosis [33], initial treatment options include chemotherapy 
and several locoregional therapies. In these cases, chemotherapy in combination 
with molecular targeted drugs is recommended, followed by curative resection if a 
response is achieved.
5.1 Chemotherapy
In patients with “favorable oncological” criteria (i.e., >50% likelihood of cure 
based on various factors including long-term metachronous disease) and “favor-
able surgical” criteria (no massive disease infiltration), both upfront surgery and 
perioperative chemotherapy are options. The EPOC study with perioperative che-
motherapy has shown no clear predilection for one option over the other, since the 
5-year OS rate reported for the perioperative chemotherapy group was 51% (95% CI 
45–58) versus 48% (95% CI 40–55) in the surgery-only group [34].
However, in cases with disease that is not technically challenging to resect but 
where the prognostic situation is unclear, perioperative chemotherapy should be 
the preferable treatment strategy. These patients should undergo perioperative 
chemotherapy, 3 months before surgery and 3 months after surgery. The preferred 
treatment in this situation should be FOLFOX (or alternatively capecitabine 
with oxaliplatin—CAPOX) as reported for the EPOC trial [34]. EGFR-targeting 
monoclonal antibodies (cetuximab and panitumumab) are not to be used in this 
setting, based on the data from the New EPOC trial [35]. No data with bevacizumab 
are available for this specific patient group; thus, bevacizumab is not indicated 
[7]. Hence, especially in the case of synchronous metastatic disease, neoadjuvant 
chemotherapy preceding liver resection is often undertaken as a way of assessing 
the natural history of metastatic disease prior to resection.
Category Contraindication
Technical
1. Absolute Impossibility of R0 resection and functional residual liver volume preserved (≥ 25–30% 
liver remnant)
Presence of unresectable extrahepatic disease
2. Relative R0 resection possible only with complex procedure (portal vein embolization, two-stage 
hepatectomy, hepatectomy combined with ablationa)
R1 resection
Oncological
1. Concomitant extrahepatic disease (unresectable)
2. Number of lesion ≥5
3. Tumor progression
Any patient should be categorized as A1 or A2/B1, B2, or B3. This classification may help to clearly define the type of 
unresectable patients included in all clinical trials.
aIncludes all methods, including radiofrequency ablation.
Table 2. 
Contraindications to hepatic resection in patients with CRC liver metastases (adapted from Adam et al. [28]).
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The use of conversion chemotherapy in clinical practice is based on the fact 
that initially unresectable tumors that are judged resectable after responding to 
chemotherapy and that undergo surgery display better long-term result than those 
treated with chemotherapy only [7, 36]. It is reported that up to 33% of patients 
with “initially unresectable” hepatic metastases have a sufficient objective response 
to conversion therapy to permit a subsequent complete (R0) resection [17, 37]. 
However, it has also been reported that the probability of downstaging a truly 
unresectable disease to the point of resectability is only up to 15 [38].
Another important aspect that has to be studied when considering conversion 
therapy is that longer durations of chemotherapy increase the possibility of liver 
toxicity and postoperative complications. Evaluation of the response through imag-
ing tests should be made each 6–8-week gap, and the resection should be made as 
soon as the metastases are considered undoubtedly resectable [38].
In this scenario the response of the disease to the systemic treatment is also very 
important. If a growth of the disease is perceived while on chemotherapy or even 
the development of extrahepatic disease appears in this period, it may indicate that 
the tumor is biologically aggressive and it would not benefit from resection [17].
After complete resection of mCRC, the best postoperative strategy is debatable 
as well. Due to the lack of published randomized trials to conduct clinical practice, 
some suggest completion of a 6-month course of systemic chemotherapy (includ-
ing courses administered as neoadjuvant therapy), as also suggested by updated 
guidelines from the National Comprehensive Cancer Network (NCCN) [38].
The strong tumor responses for mCRC with the new agents in chemotherapy can 
even reach a complete response status. The tumors with less than 2 cm in diameter 
and more than 1 cm deep in the hepatic parenchyma are the ones with greater risk 
of vanishing [39]. Nevertheless, the resection is still needed considering that true 
pathologic complete response or clinical long-term response is, after chemotherapy 
alone, present in only 17% of the patients [40]. Therefore, those at risk of disap-
pearing with the neoadjuvant treatment should be marked with a fiducial marker 
such as a coil before chemotherapy [41].
5.2 Radiofrequency ablation therapy
Though resection is considered the gold standard care of mCRC, sometimes 
there are contraindications due to anatomical reasons. Additionally, there may be 
comorbidities or liver dysfunction associated which grades the patient as ineligible 
for major surgery. In these cases, radiofrequency ablation (RFA) represents a great 
alternative [21].
Considered as a parenchymal-sparing approach, the ablation therapy has been 
used for managing tumors that can vary from small to unresectable. It can be used 
as part of a combined ablation/resection tactic in cases of borderline resectable 
tumors or cases with risk of insufficient future liver remnant [17]. In a multicenter 
study of 288 patients who underwent combined intraoperative ablation and resec-
tion of mCRC, the 5-year overall survival was 37%, and local recurrence-free 
survival from ablated lesions was 78%. Postoperative mortality was 1%, and the 
overall complication rate was 35% [42].
5.3 ALPPS
Associating liver partition and portal vein ligation for staged hepatectomy 
(ALPPS) has emerged as modification on classic two-staged hepatectomy (TSH) 
with portal vein embolization. This new concept of liver resection, ALPPS, was 
first described in 2011 [43]. The main advantage of ALPPS is its ability to generate 
7Colorectal Liver Metastases
DOI: http://dx.doi.org/10.5772/intechopen.80558
extensive and accelerated hypertrophy of the future liver remnant (FLR), achiev-
ing adequate volume for completion of the second stage of the ALPPS in as short as 
1 week. This method for hepatic resection has also been described to treat various 
hepatic tumors in children [44]. ALPPS brings solution to a major flaw of classic 
TSH, where a considerable percentage (≈30%) of patients are unable to complete 
the second stage due to insufficient future liver remnant (FLR) growth and short-
interval progression of the disease [45].
In the initial study, 68% of the patients experienced complications, and the 
surgical mortality rate was 12% [43]. Since the first description of ALPPS, there has 
been a great deal of interest in this treatment. However, criticism of the approach 
has been raised mainly regarding surgical morbidity and mortality [46].
Recently, Wanis et al. [47] reported a cohort of 58 patients who underwent 
ALPPS for colorectal liver metastases. They observed no perioperative mortalities 
and a rate of severe complications of 21%. The 3-year post-ALPPS overall survival 
was 50%, while the disease-free survival was 13%. The most common site of first 
recurrence was the liver alone (38%). Patient-reported quality of life after ALPPS 
was similar to reference values for general population
Additionally, the Scandinavian Multicenter Randomized Controlled Trial 
(LIGRO Trial) comparing ALPPS with TSH [48], showed a much higher resection 
rate for ALPPS, 92% (44/48), than TSH, 57% (28/49) (P < 0.0001). Considering 
other parameters, such as complications [43% (19/44) vs. 43% (12/28)] and 90-day 
mortality [8.3% (4/48) vs. 6.1% (3/49)] or R0 RRs [77% (34/44) vs. 57% (16/28)], 
no differences were observed.
In experienced hepatobiliary centers and in well-selected patients, ALPPS can be 
performed with low perioperative morbidity and minimal to no mortality, resulting 
in good intermediate-term survival and excellent quality of life [47].
Although many centers have been using ALPPS associated with right hepatectomy 
with good results to treat liver mCRC, indications for ALPPS should continue to be 
scrutinized critically by multidisciplinary tumor boards based on accepted criteria of 
remnant liver volume, number of prior cycles of chemotherapy, and histologic criteria 
of the presence or absence of underlying parenchymal hepatic damage based on at the 
least a fresh frozen section during stage 1, when considering ALPPS [49].
The technique consists of a bilateral subcostal laparotomy using an adult sub-
costal retractor. A thorough inspection of the abdominal cavity is carried out in 
order to detect any previously missed metastases. A cholecystectomy and hepatic 
hilum dissection are then performed. The right and left hepatic arteries, as well as 
the arteries for segment 4, were dissected and identified. The common bile duct 
was dissected. The left or right portal vein is ligated. When the tumor is located on 
the right hemi-liver with involvement of segment 4, the portal branch for segment 
4 is ligated and divided. Full mobilization of the liver is obtained by sectioning the 
falciform, coronary, and right and left triangular ligaments of the liver. The right 
or left hepatic vein of the liver to be resected is dissected and encircled with a vessel 
loop, as seen in Figure 1. An intraoperative ultrasound is performed to verify a 
tumor-free parenchymal transection line.
The liver parenchyma is transected using combined ultrasonic energy 
(Ultracision®), monopolar and bipolar electrocautery, and ligation of the blood 
vessels and bile ducts. Biologic fibrin sealant can be used in both surfaces of the 
spitted liver. Closed drainage is placed in the liver hilum. We do not use any plastic 
film, mesh, or plastic bag to separate both surfaces of the liver. Metastases located in 
the future remnant liver (FRL) can be treated either by local resection or radiofre-
quency tumor ablation (RFA).
During the second operation, the hepatic artery and the bile duct of the diseased 
liver are ligated and transected. A clamp is applied at the right or left hepatic vein, 
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and the vein is then transected. A 4–0 Prolene® running suture is applied to the 
stump of the hepatic vein. Liver segment 1 is usually preserved [46].
6. Timing for surgical approach
When facing a situation of synchronous disease, with both primary tumor and 
hepatic metastases, the timing for surgical approach of the hepatic lesions is still a 
topic of discussion.
The lesions can be accessed simultaneously in one procedure, or they can be 
treated with a staged resection. In the staged manner, there is the classic approach, 
which means accessing the primary tumor first; and there is the reverse approach, 
also known as liver-first approach. No difference has been shown by various stud-
ies, regardless of which method is used [50].
Therefore, the decision should be established on a case-by-case basis, con-
sidering the symptoms presented by the patient, location, size, and possible 
complications of each one such as bowel perforation, risk of liver failure, whether 
the patient underwent chemotherapy or not, performance status, and the surgeon 
expertise [17, 51].
7. Surgical resection
The surgical approach of the mCRC in the liver can be performed through an 
anatomic resection or a nonanatomic/parenchymal-sparing resection (PSR). Since 
the type of resection has not been associated with significant differences in rates of 
positive margin, recurrence, or survival [50], and considering that the PSR pre-
serves greater hepatic reserve, recent studies are leaning toward the nonanatomic 
method, particularly when chemotherapy-induced liver injury is a concern [17].
Keeping in mind that recurrences after initial resection of mCRC can occur in 
up to 57% of cases and the most common site of recurrences is the liver [52] and 
considering that repeat liver resection in a second recurrence, with satisfactory 
Figure 1. 
Postoperative CT image of a patient who underwent portal vein ligation and staged hepatectomy: (a) treated 
liver metastases of the FRL, (b) metastases on liver to be resected, and (c) line of liver bipartition.
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morbidity and perioperative mortality, has been associated with a 5-year survival 
up to 43% [38], the PSR becomes an even more attractive option.
Considering the width of the resection margin, a 2017 meta-analysis reported 
that margins greater than 10 mm were related with superior 5-year OS [53]. Still, 
numerous retrospective studies revealed that less than 10 mm but negative margin 
is not related with poorer survival [54]. In a multicenter study of 551 patients, surgi-
cal margins were classified as positive or negative with 1–4, 5–9, and >10 mm of 
tumor-free parenchyma. The positive margins were associated with a greater risk of 
recurrence, and the width of negative margins did not affect survival, recurrence, 
or site of recurrences [54].
There is one situation where anatomic resection and/or a wider surgical margin 
(>10 mm) may be indicated which is before a RAS-mutated mCRC as it constitutes 
a more aggressive tumor biology group and has been associated with more positive 
margins and worse survival after surgery [55]. Others reported that even a wider 
resection margin might not be sufficient to overcome the aggressive tumor biology 
associated with a RAS mutation. In a study of 411 patients who underwent resec-
tion for mCRC at Johns Hopkins University, a 1–4-mm margin was associated with 
improved survival compared with a positive margin (<1 mm or R1) for wild-type 
KRAS tumors, with which a wider resection margin did not further improve sur-
vival. In KRAS-mutated tumors, however, negative margin status, which included a 
1-cm margin, did not improve survival [56].
8. Follow-up after resection
According to the consensus-based guidelines from the National Comprehensive 
Cancer Network (NCCN), the recommendation is carcinoembryonic antigen 
(CEA) testing every 3–6 months for 2 years followed by every 6 months for 3 years; 
computed tomography (CT) of the chest/abdomen and pelvis every 3–6 months for 
2 years and then every 6–12 months up to a total of 5 years; colonoscopy in 1 year; 
if negative, repeat in 3 years and then every 5 years; and if advanced adenoma is 
found, repeat in 1 year [38].
An important point is that posttreatment follow-up should only be performed 
for those patients considered candidate for a second potentially curative surgical 
procedure [38].
9. Repeat resection for colorectal liver metastases
Re-resection for recurrence of mCRC is a safe and viable option in properly 
selected patients. In order to prevent post-hepatectomy liver failure, sufficient 
future liver reserve is paramount, as well as no evidence of extrahepatic disease and 
good performance status [57–59].
Although randomized trials have not been conducted to prove benefit, several 
reported series have demonstrated perioperative mortality rates lower than 5%, and 
overall survival rates ranged from 20 to 43% at 2–5 years [57–59].
Patients with a relapse-free interval of longer than 1 year appear to have a more 
favorable outcome from re-resection. Factors associated with a poor outcome 
include synchronous resection for the first liver metastases and the presence of 
multiple lesions at second hepatectomy [60, 61].
Interestingly, recurrences at the margin are uncommon [62, 63]. Some studies 
have reported 5-year overall survival rates after re-resection of 33–73% with no 
perioperative mortality [64, 65].
Surgical Challenges in the Management of Liver Disease
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10. Conclusion
It is known that the majority of metastatic CRC liver disease will be potentially 
resectable at the time of diagnosis. Considering that hepatic resection is the only 
curative option for these patients, the parameters of resectability have expanded 
through the years due to a wider knowledge of the disease, improving diagnostic 
techniques, new drugs, and technical surgical advances. It is safe to say that the 
treatment strategies have advanced rapidly enough to change dramatically the 
natural history of the mCRC.
ALPPS has been recently introduced as an option to the treatment of mCRC. It 
has been shown to increase drastically the resection rates, with complications rates 
not different from standard two-staged hepatectomy.
Several treatment options are available to treat patients with mCRC. It is impor-
tant to have in mind that the treatment approach must be established for each case. 
Not only the patient and anatomic factors are important, but also the tumor factors 
must be considered. Best results are obtained when the treatment approaches for 
individual patients are discussed within a multidisciplinary team (MDT) of experts, 
meeting regularly as a tumor board to review mCRC cases.
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